We are live on ! Find out more
IBER

Ibere Pharmaceuticals
IBER

Delisted

IBER was delisted on the 1st of March, 2023.

Back to rankings

47 hedge funds and large institutions have $126M invested in Ibere Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

5% more capital invested

Capital invested by funds: $120M → $126M (+$6.18M)

2% less funds holding

Funds holding: 48 → 47 (-1)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

Holders
47
Holders Change
-1
Holders Change %
-2.08%
% of All Funds
0.76%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
7
Reduced
5
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HSBC Holdings
HSBC Holdings
United Kingdom
+$3.25M
2
AC
Aristeia Capital
Connecticut
+$2.5M
3
WCMNY
Westchester Capital Management (New York)
New York
+$2.44M
4
GCL
Glazer Capital LLC
New York
+$2.44M
5
HIM
HGC Investment Management
Ontario, Canada
+$490K

Top Sellers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
-$2.44M
2
Citadel Advisors
Citadel Advisors
Florida
-$2.26M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.25M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$529K
5
PI
PEAK6 Investments
Illinois
-$496K
Name Holding Trade Value Shares
Change 		Change in
Stake
GCL
1
Glazer Capital LLC
New York
$13.4M +$2.44M +243,601 +22%
MF
2
Magnetar Financial
Illinois
$7.93M – – –
Hudson Bay Capital Management
3
Hudson Bay Capital Management
Connecticut
$7.23M – – –
PAMP
4
Polar Asset Management Partners
Ontario, Canada
$6.85M – – –
AC
5
Aristeia Capital
Connecticut
$6.81M +$2.5M +250,000 +59%
Millennium Management
6
Millennium Management
New York
$6.67M +$80K +8,000 +1%
FTCM
7
First Trust Capital Management
Illinois
$5.48M – – –
Marshall Wace
8
Marshall Wace
United Kingdom
$5.45M – – –
PC
9
Periscope Capital
Ontario, Canada
$4.75M +$142K +14,225 +3%
KL
10
KIM LLC
Kansas
$4.54M – – –
LA
11
Linden Advisors
New York
$4.54M – – –
SC
12
Sculptor Capital
New York
$4.29M – – –
VI
13
Vestcor Inc
New Brunswick, Canada
$4.04M – – –
SCM
14
Saba Capital Management
New York
$3.59M +$267K +26,700 +8%
CM
15
Cohanzick Management
New York
$3.48M -$31K -3,100 -0.9%
RCM
16
Radcliffe Capital Management
Pennsylvania
$3.3M – – –
HSBC Holdings
17
HSBC Holdings
United Kingdom
$3.28M +$3.25M +325,108 New
Bank of America
18
Bank of America
North Carolina
$3.23M – – –
Nomura Holdings
19
Nomura Holdings
Japan
$3.21M – – –
MCM
20
Moore Capital Management
New York
$3.03M – – –
CCA
21
Castle Creek Arbitrage
Colorado
$2.56M – – –
WCMNY
22
Westchester Capital Management (New York)
New York
$2.46M +$2.44M +243,944 New
AA
23
AQR Arbitrage
Connecticut
$2.08M – – –
PMAM
24
Picton Mahoney Asset Management
Ontario, Canada
$2.02M – – –
D.E. Shaw & Co
25
D.E. Shaw & Co
New York
$1.51M -$1.25M -125,008 -45%
1
2 3

IBER Hedge Fund Activity: Q4 2022 in Review

47 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals (IBER) for Q4 2022, worth a combined $126M — up 5.2% from $120M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of IBER and 6 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 7 added.

The largest buyer was HSBC Holdings, opening a new position worth an estimated $3.25M. The largest seller was Cowen and Company, exiting entirely with an estimated $2.44M sold.

  • 47 institutional investors held Ibere Pharmaceuticals (IBER) as of Q4 2022, down from 48 in Q3 2022.
  • Funds reported $126M of Ibere Pharmaceuticals stock for Q4 2022, up 5.2% quarter-over-quarter.
  • 6 funds opened new Ibere Pharmaceuticals positions in Q4 2022 and 7 closed out, a net change of -1 holder.
  • The largest Ibere Pharmaceuticals buyer in Q4 2022 was HSBC Holdings, an estimated $3.25M added.
  • The largest Ibere Pharmaceuticals seller in Q4 2022 was Cowen and Company, an estimated $2.44M sold.

Based on aggregated 13F filings for Q4 2022.